skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiation-induced hypothyroidism in patients with breast cancer: a retrospective analysis of 243 cases

Journal Article · · Medical Dosimetry
 [1]; ; ;  [1];  [2]
  1. Necmettin Erbakan University Meram Medicine School, Department of Radiation Oncology, Akyokus Mevkii, Konya 42090 (Turkey)
  2. Necmettin Erbakan University Meram Medicine School, Department of Public Health and Biostatistics, Akyokus Mevkii, Konya 42090 (Turkey)

This study aims to estimate the incidence of hypothyroidism (HT) and to evaluate the predictors affecting the development of HT after radiotherapy (RT) for breast cancer, with a focus on radiation dose-volumetric parameters. Between 2009 and 2015, 243 patients undergoing RT for breast cancer were retrospectively analyzed. Free triiodothyronine (FT3), free thyroxin (FT4), and thyrotropin (TSH) were monitored before and after RT. The relation between the doses to thyroid gland (D{sub mean}, D{sub max}, D{sub min}), percentage of thyroid volume receiving > 10 Gy, 20 Gy, 30 Gy, 40 Gy, and 50 Gy (V10 to V50), absolute thyroid volume, and HT were analyzed. The risk of HT according to radiation fields and the other clinic factors were also evaluated. The median follow-up was 41 (range; 6 to 130) months. Sixty-seven percent of the patients received RT to the breast/chest wall and ipsilateral supraclavicular fossa. Of 243 patients, 51 (21%) were diagnosed with HT. The median time to the onset of HT was 27 (range; 5 to 64) months. There were no significant relationships observed between D{sub min} or V10 to V50 and HT. The surgery type, clinical stage, nodal status, RT field, D{sub mean}, and D{sub max} were statistically significant predictors for HT in univariate analysis. The D{sub mean} was the only prognostic factor predicting HT in multivariate analysis, and D{sub mean} > 21 Gy was a threshold value for the evolvement of HT. In this study, we present evidence that postoperative irradiation of patients with breast cancer may frequently lead to HT. Patients who have received RT for breast cancer, especially irradiation on the supraclavicular region, may require thyroid function screening after RT.

OSTI ID:
22701693
Journal Information:
Medical Dosimetry, Vol. 42, Issue 3; Other Information: Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0958-3947
Country of Publication:
United States
Language:
English

Similar Records

Thyroid V30 Predicts Radiation-Induced Hypothyroidism in Patients Treated With Sequential Chemo-Radiotherapy for Hodgkin's Lymphoma
Journal Article · Sun Apr 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22701693

Thyroid-Stimulating Hormone Suppression for Protection Against Hypothyroidism Due to Craniospinal Irradiation for Childhood Medulloblastoma/Primitive Neuroectodermal Tumor
Journal Article · Mon Oct 01 00:00:00 EDT 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22701693

Predictor of Severe Gastroduodenal Toxicity After Stereotactic Body Radiotherapy for Abdominopelvic Malignancies
Journal Article · Thu Nov 15 00:00:00 EST 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22701693